Immatics N.V. (IMTX) is a biopharmaceutical company that specializes in developing innovative immunotherapies for the treatment of cancer. The company utilizes a unique approach called T-cell receptor (TCR) redirection, which harnesses the power of the immune system to selectively target and eliminate cancer cells. This cutting-edge technology has shown great promise in early clinical trials, with potential to revolutionize the field of cancer treatment.

To assess the technical outlook for Immatics N.V. (IMTX) stock, various technical indicators can be utilized. The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. By analyzing the RSI, investors can identify overbought and oversold conditions, providing potential trading opportunities.

Immatics N.V. (IMTX) Technical Analysis

Discover the technical analysis indicators for Immatics N.V. (IMTX) stock including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Gain insights into the stock's performance using these key indicators.

Immatics N.V. (IMTX) Technical Analysis - Stock RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Immatics N.V.

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	64.11	Neutral	22.7%
auto_graphMACD	21.39	Neutral	205.0%
auto_graphCCI	90.68	Neutral	59.5%
auto_graphADX	32.44	Neutral	-
auto_graphATR	20.20	Buy	-
auto_graphWILLR	-22.65	Neutral	156.7%
auto_graphROC	37.14	Neutral	201.9%
auto_graphSTOCHRSI	0.00	Buy	-98.9%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Immatics N.V. (IMTX) Technical Analysis

Keep an eye on Immatics N.V.

Frequently Asked Questions

What are the technical signals for Immatics N.V. (IMTX) stock based on the last 30 days?

Take Your Investments to a Whole New Level